Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intertriginous

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Intertriginous. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005501-22 Sponsor Protocol Number: LEO 80190-O23 Start Date*: 2008-04-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004782-18 Sponsor Protocol Number: LEO 80190-O21 Start Date*: 2008-06-03
    Sponsor Name:LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)
    Full Title: Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/...
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LV (Completed) CZ (Completed) SI (Completed) NL (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010963-18 Sponsor Protocol Number: LEO80190-O25 Start Date*: 2009-09-29
    Sponsor Name:LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)
    Full Title: A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with hydrocortisone 10 mg/g ointment, both applied once daily in the treatmen...
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003365-41 Sponsor Protocol Number: LEO 80190-O22 Start Date*: 2008-01-10
    Sponsor Name:LEO Pharma A/S
    Full Title: Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment co...
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016627-56 Sponsor Protocol Number: H552000-0920 Start Date*: 2009-12-23
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A phase IIa, multi-center, randomized, double-blind study to evaluate the anti-mycotic and anti-inflammatory efficacy of topical combinational product LAS 41003 versus corresponding mono-substances...
    Medical condition: 96 male or female patients with candida infections in intertriginous areas at the trunk will be randomized
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002209-23 Sponsor Protocol Number: V01-122A-401 Start Date*: 2020-07-22
    Sponsor Name:Bausch Health Americas, Inc.(affiliate of Bausch Health US ,formerly known as Dow Pharmaceutical Sciences)
    Full Title: A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion i...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000556-95 Sponsor Protocol Number: LP0053-1004 Start Date*: 2017-01-03
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 90100 twice weekly maintenance regimen for psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003845-40 Sponsor Protocol Number: 122-0551-209 Start Date*: 2019-07-09
    Sponsor Name:Mayne Pharma LLC
    Full Title: An open label evaluation of the adrenal suppression potential and pharmacokinetic properties of twice daily halobetasol propionate foam, 0.05% in subjects 12 to less than 18 years of age with plaqu...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006704-10 Sponsor Protocol Number: MICUMA Start Date*: 2007-03-16
    Sponsor Name:JADO Technologies GmbH
    Full Title: Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis
    Medical condition: chronic stable symptomatic maculopapulous cutaneous mastocytosis or systemic mastocytosis with involvement of the skin and with positive Darier´s sign
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012812 Diffuse cutaneous mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004275-11 Sponsor Protocol Number: CASM981M2308 Start Date*: 2005-03-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks.
    Medical condition: Seborrheic dermatitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002861-20 Sponsor Protocol Number: 2012-01 Start Date*: 2014-01-07
    Sponsor Name:Lek Pharmaceuticals d.d.
    Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...
    Medical condition: Chronic stable plaque psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000276-34 Sponsor Protocol Number: CAIN457F2306 Start Date*: 2011-08-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years ...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) GB (Completed) DE (Completed) BG (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000435-13 Sponsor Protocol Number: JWGKDVAAP0117 Start Date*: 2017-11-13
    Sponsor Name:University Hospital Frankfurt for its Dermatology Department, Clinical Research
    Full Title: Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatmen...
    Medical condition: Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001568-12 Sponsor Protocol Number: 16-02/CalciBet-S Start Date*: 2016-10-18
    Sponsor Name:Dermapharm AG
    Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...
    Medical condition: chronic stable plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-018355-10 Sponsor Protocol Number: H553000-1001 Start Date*: 2010-06-18
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Two Active Controls in a Psoriasis-P...
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 6 months
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022281-27 Sponsor Protocol Number: H553000-1005 Start Date*: 2010-12-20
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of different formulations of LAS 41004 Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 6 months
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001384-45 Sponsor Protocol Number: H553000-1101 Start Date*: 2011-06-29
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A 22 day bland ointment and reference-controlled, investigator-blind, single center, randomized, proof of concept clinical study with an intraindividual comparison investigating the anti-psoriatic ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004508-23 Sponsor Protocol Number: EXP-1372 Start Date*: 2018-02-08
    Sponsor Name:LEO Pharma A/S
    Full Title: Capture of LEO 90100 medication usage with digital tracker and evaluation of efficacy in patients with psoriasis
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000003-20 Sponsor Protocol Number: MEMPSOLAR0001 Start Date*: 2021-06-08
    Sponsor Name:Aarhus University Hospital
    Full Title: AN INVESTIGATOR INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE RESIDUAL DISEASE MEMORY IN PSORIASIS SKIN DURING ENSTILAR® AND NARROW-BAND ULTRAVIOLET B THERAPY. ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003900-28 Sponsor Protocol Number: TOFA-PREDICT Start Date*: 2018-04-04
    Sponsor Name:UMC Utrecht
    Full Title: A Stratification trial to determine key immunological factors predicting Tofacitinib efficacy in Psoriatic Arthritis (PsA). TOFA-PREDICT
    Medical condition: psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 20:03:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA